您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > PD-1/PD-L1 Inhibitor 3
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
PD-1/PD-L1 Inhibitor 3
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
PD-1/PD-L1 Inhibitor 3图片
CAS NO:1629654-95-0
包装与价格：
包装价格(元)
1mg电议
5mg电议

产品介绍
PD-1/PD-L1 Inhibitor 3 是一种大环肽，是一种有效且选择性的 PD-1/PD-L1 和 CD80/PD-L1 相互作用抑制剂，从专利 WO2014151634A1 化合物 No.1 中提取。 PD-1/PD-L1 Inhibitor 3 通过与 PD-L1 结合来干扰 PD-L1 与 PD-1 和 CD80 的结合，IC50 分别为 5.60 nM 和 7.04 nM。 PD-1/PD-L1 Inhibitor 3可用于多种疾病的研究，包括癌症和传染病。
Cas No.1629654-95-0
化学名(3S,6S,12S,15S,18S,21S,24S,27S,30R,39S,42S,47aS)-3-((1H-imidazol-5-yl)methyl)-12,18-bis((1H-indol-3-yl)methyl)-N,42-bis(2-amino-2-oxoethyl)-36-benzyl-21,24-dibutyl-27-(3-guanidinopropyl)-15-(hydroxymethyl)-6-isobutyl-8,20,23,38,39-pentamethyl-1,4,7,10,13,
Canonical SMILESO=C(NCC(N)=O)[C@H]1NC([C@@H](NC([C@@H](N(C)C([C@H](CCCC)N(C)C([C@H](CC2=CNC3=C2C=CC=C3)NC([C@H](CO)NC([C@H](CC4=CNC5=C4C=CC=C5)NC(CN(C)C([C@H](CC(C)C)NC([C@@H](NC([C@H]6N(C([C@H](CC(N)=O)NC([C@@H](N(C(C(NC(CSC1)=O)CC7=CC=CC=C7)=O)C)C)=O)=O)CCC6)=O)CC8=CN=
分子式C89H126N24O18S
分子量1852.17
溶解度Soluble in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

PD-1/PD-L1 Inhibitor 3 is a PD-1/PD-L1 interaction inhibitor.

The anti-PD-1 and anti-PD-L1 compounds have been found to show impressive antitumor effects in various malignancies, such as melanoma. The greatest clinical outcome in unselected patients has been observed in melanoma. The tumor expression of PD-L1 is suggested to be a suggestive, inadequate, and predictive of response to immune-checkpoint blockade.

In vitro: PD-1/PD-L1 inhibitor 3 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (PD-1) with its ligand protein (PD-L1) and with CD80. PD-1/PD-L1 inhibitor 3 was also found to act as an immunomodulator. In addition, PD-1/PD-L1 Inhibitor 3 was found to have highly efficacious binding to PD-L1 and promote the increased functional activities of T cells. Therefore, PD-1/PD-L1 inhibitor 3 could be regarded as a promising therapeutic treatment of cancer and infectious diseases, such as hepatitis C [1].

In vivo: So far, there is no animal in vivo study reported for PD-1/PD-L1 Inhibitor 3.

Clinical trial: Up to now, PD-1/PD-L1 Inhibitor 3 is still in the preclinical development stage.

References:
[1] MILLER Michael Matthew, et al. Patent, Pub. No.:WO/2014/151634